BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Avenue Therapeutics, Inc. ATXI
10 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.4M
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-125.7%
Net margin · FY25
-207.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.4M
Revenue, FY2025 · full 10-year series below
Revenue
Net income
The company lost 207 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-125.7%
Return on equity, FY2025
ROE
Operating margin-219.6%
Net margin-207.2%
Return on assets-103.8%
Each USD of equity lost 126 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.9M
total assets, end of FY2025
Total assetsUSD 2.9M
EquityUSD 1.8M
CashUSD 2.9M
Equity funds 63% of total assets.
History
10 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.0
0.0
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
−0.22
−0.31
−1.65
−2.10
−1.85
−1.11
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
ROE %
−125.7
−532.2
−382.3
−98.0
−128.4
−112.5
−839.9
−229.9
−220.2
·
Shares out B
0.00
0.00
0.00
0.00
0.00
0.02
0.02
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
29 of 30
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed